| __timestamp | Blueprint Medicines Corporation | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 20622000 |
| Thursday, January 1, 2015 | 14456000 | 33837000 |
| Friday, January 1, 2016 | 19218000 | 35979000 |
| Sunday, January 1, 2017 | 27986000 | 25003000 |
| Monday, January 1, 2018 | 47928000 | 19269000 |
| Tuesday, January 1, 2019 | 96388000 | 15426000 |
| Wednesday, January 1, 2020 | 157743000 | 14456000 |
| Friday, January 1, 2021 | 195293000 | 20488000 |
| Saturday, January 1, 2022 | 237374000 | 27195000 |
| Sunday, January 1, 2023 | 295141000 | 30914000 |
| Monday, January 1, 2024 | 359272000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing operational expenses is crucial for success. Blueprint Medicines Corporation and Celldex Therapeutics, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
Since 2014, Blueprint Medicines has seen a staggering increase in SG&A expenses, growing by over 3,600% from 2014 to 2023. This reflects their aggressive expansion strategy, with expenses peaking at nearly $295 million in 2023.
In contrast, Celldex Therapeutics has maintained a more stable SG&A expense profile, with a modest increase of around 50% over the same period. Their expenses reached approximately $31 million in 2023, indicating a more conservative approach.
These trends highlight the diverse strategies within the biotech sector, where companies balance growth ambitions with financial prudence.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? GSK plc or Celldex Therapeutics, Inc.
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Blueprint Medicines Corporation
Comparing SG&A Expenses: Biogen Inc. vs Blueprint Medicines Corporation Trends and Insights
Selling, General, and Administrative Costs: Genmab A/S vs Celldex Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Dr. Reddy's Laboratories Limited or Blueprint Medicines Corporation
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Celldex Therapeutics, Inc.
Blueprint Medicines Corporation or Grifols, S.A.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Corcept Therapeutics Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Soleno Therapeutics, Inc. Trends and Insights
Veracyte, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?